Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Positive 53.5%

Neg 0% Neu 0% Pos 53.5%

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $8.